Notice Number: NOT-CA-19-066
Key Dates
Release Date: August 2, 2019
Issued by
NATIONAL CANCER INSTITUTE (NCI)
Purpose
The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating in PAR-19-326, "Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care in Low and Middle-Income Countries (R21 Clinical Trial Optional)."
The following changes have been made to reflect NCI's participation in this FOA:
Part 1. Overview Information
Components of Participating Organizations
Fogarty International Center (FIC)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Cancer Institute (NCI)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.989, 93.279, 93.242, 93.393, 93.394, 93.395, 93.399
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
[This section is appended with following statement of NCI's interests.]
In addition to research areas listed in the Funding Opportunity Description, NCI is interested in applications that address the following scientific gaps:
Section VII. Agency Contacts
The following contacts have been added:
Scientific/Research Contacts
Geraldina Dominguez, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-781-3291
Email: domingug@mail.nih.gov
Financial/Grants Management Contact(s)
Shane Woodward
National Cancer Institute (NCI)
Telephone: 240-276-6303
Email: woodwars@mail.nih.gov
All other aspects of this FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Geraldina Dominguez, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-781-3291
Email: domingug@mail.nih.gov